Verastem | VSTM - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
AstraZeneca USD 12.61B 225M 2026-03
Curis USD 1.14M 8.86M 2025-12
Cytokinetics USD 19.2M 1.44M 2026-03
Gilead Sciences USD 5.52B 791M 2026-03
Incyte USD 1.17B 217.51M 2026-03
Laboratory Of America USD 1.01B 20.6M 2026-03
Novartis USD 10.07B 184M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Roche Holding CHF 22.09B 10.04B 2025-12
TG Therapeutics USD 171.41M 16.98M 2026-03
Verastem USD 14.64M 14.1M 2025-12